Riskpilot← Back to searchSign inGet full accessCyteGuard AB
ABActiveOrg 5592180813Sollentunavägen 144All other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20190 employees
Revenue 2024
SEK 0
EBITDA margin
—
-14% vs 2023
Equity ratio
17.8%
Financial strength
Net profit 2024
SEK -12K
+54% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -8K | -14% |
| Net profit | SEK -12K | +54% |
| Total assets | SEK 1,1M | -1% |
| Equity | SEK 202K | -6% |
| Employees | 0 | — |
Legal name
CyteGuard AB
Org number
5592180813
Legal form
Aktiebolag
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
11 september 2019
Share capital
SEK 200 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Utveckling av kvalitetskontroll av trombocyter och därmed förenlig verksamhet.
Address
Sollentunavägen 144
Email
goran.nilsson@orange.fr
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −33 | −16 | −10 | −7 | −8 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −33 | −16 | −10 | −7 | −8 |
| Net financials | — | — | — | −19 | −4 |
| Profit before tax | −33 | −16 | −10 | −26 | −12 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −33 | −16 | −10 | −26 | −12 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 866 | 933 | 1 091 | 1 146 | 1 135 |
| Equity | 67 | 251 | 241 | 215 | 202 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 799 | 682 | 850 | 931 | 932 |
| Total debt | 799 | 682 | 850 | 931 | 932 |
EBITDA margin
-800000.0%
This company
15.8%
Market median
-5063391% vs market
20202024
Equity ratio
17.8%
This company
38.2%
Market median
-53% vs market
20202024
Return on equity
-5.9%
This company
18.4%
Market median
-132% vs market
20202024
Net profit margin
-1200000.0%
This company
8.1%
Market median
-14814915% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
4.62×
This company
0.62×
Market median
-645% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2021 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CyteGuard AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Göran Nilsson | Chairman | 0 companies |
| Per Olof Hvass | Board of Directors | 0 companies |
| Ralf Gutlein | Board of Directors | 0 companies |
| Britt Elisabet Nilsson | Deputy Board Member | 0 companies |
| Ulrich Lothar Benz | Board of Directors | 0 companies |